• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cantor Fitzgerald initiated coverage on BioVie Inc. with a new price target

    7/22/22 7:51:28 AM ET
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIVI alert in real time by email
    Cantor Fitzgerald initiated coverage of BioVie Inc. with a rating of Overweight and set a new price target of $7.00
    Get the next $BIVI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIVI

    DatePrice TargetRatingAnalyst
    7/22/2022$7.00Overweight
    Cantor Fitzgerald
    11/30/2021$50.00 → $27.00Buy
    B. Riley Securities
    More analyst ratings

    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

      CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase 2 clinical trial will be presented at the Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27-30, 2025. People with Parkinson's disease (PD) often face barriers to accessing specialized care and participating in clinical trials due to delayed diagnos

      6/26/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

      CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in poster session at the upcoming Advanced Therapeutics in Movement & Related Disorders® Congress, to be held at National Harbor, MD, from June 27 to June 30, 2025. Details for the poster session are as follows: Title: SUN

      6/24/25 4:05:00 PM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

      Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1 Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzheimer's disease and Parkinson's disease trials thought to be driven by neuroinflammation CARSON CITY, Nev., May 15, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"

      5/15/25 8:00:00 AM ET
      $BIVI
      Biotechnology: Pharmaceutical Preparations
      Health Care